Document is current
Any future updates will be listed below
-
Authors
Torres, Antoni https://orcid.org/0000-0002-8643-2167
Cilloniz, Catia https://orcid.org/0000-0002-4646-9838
Niederman, Michael S. https://orcid.org/0000-0003-0293-386X
Menéndez, Rosario
Chalmers, James D.
Wunderink, Richard G. https://orcid.org/0000-0002-8527-4195
van der Poll, Tom
- License Information
-
More Information
Article History
Accepted: 26 February 2021
First Online: 8 April 2021
Competing interests
: A.T. has been a paid consultant to Pfizer, Jansen, and MSD, and a speaker for Pfizer and MSD. M.S.N. has received research grants from Shionogi, Bayer and Merck. He has been a paid consultant to Bayer, Merck, Paratek, Abbvie, Nabriva, and Thermo-Fisher. J.D.C. has received research funding from Astrazeneca, Boehringer-Ingelheim, Gilead Sciences, Glaxosmithkline, Insmed and Novartis; he has received consultancy fees from Chiesi, Grifols and Zambon. R.G.W. is a consultant to Merck, Shionogi, Polyphor, Microbiotix, bioMerieux, Curetis, KBP Biosciences, Idorsia and Accelerate. All other authors declare no competing interests.
